Karyopharm misses earnings by $1.01, beats revenue forecasts
Biopharma firm Karyopharm reported adjusted earnings of $0.05 per share, missing estimates by $1.01, while revenue of $125.3 million exceeded expectations.
Karyopharm Therapeutics Inc. reported second-quarter earnings that fell short of analyst projections despite revenue exceeding forecasts, highlighting challenges in its commercial strategy.
The biopharmaceutical company posted adjusted earnings of $0.05 per share, missing the consensus estimate of $1.06 by $1.01. Revenue totaled $125.3 million, surpassing the expected $118.5 million, according to Refinitiv data.
Karyopharm’s revenue growth was driven by higher sales of its cancer drug Xpovio, which remains its primary revenue driver. However, the earnings miss reflects continued pressure on profitability amid competitive market dynamics and operational costs.
The company’s net loss widened to $120.7 million from $95.2 million in the same period last year, primarily due to increased research and development expenses and commercialization efforts for Xpovio.
Karyopharm maintained its full-year revenue guidance of $450 million to $500 million, reaffirming confidence in its long-term commercial strategy despite the quarterly shortfall. Shares were down 3.2% in after-hours trading following the release.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →